Key Takeaways Ionis beat Q4 estimates, but shares fell 5% on a softer-than-expected 2026 revenue outlook.Commercial revenues jumped 64%, driven by Tryngolza sales and Dawnzera's first full quarterIonis guides 2026 revenues of $800M-$825M, below estimates, citing slower new drug uptakeIonis Pharmaceuticals (IONS) reported fourth-quarter 2025 adjusted loss per share of $1.14, narrower than the Zacks Consensus Estimate of a loss of $1.21. In the year-ago period, the company had incurred an adjusted loss of 43 ...

Core Insights - SHINE Technologies has raised $240 million in equity funding to advance its commercial fusion technology [1] - The company appointed Dr. Patrick Soon-Shiong to its board, enhancing its leadership in fusion and cancer treatment [1] - The funding round was led by NantWorks, with participation from several notable investors, indicating strong investor confidence [1] Company Developments - SHINE's commercial fusion technology includes neutron testing for defense and aerospace, and radioisotopes for cancer therapies [1] - The investment marks the beginning of SHINE's next growth phase, focusing on recycling used nuclear fuel and commercial fusion energy production [1] - SHINE has raised over $1 billion in total funding, reflecting sustained investor confidence in its path to fusion energy [1] Strategic Partnerships - A strategic partnership with NantWorks includes priority access arrangements for Lu-177 supply, aimed at advancing targeted cancer treatment [1] - Dr. Soon-Shiong's investment of $150 million is part of this partnership, emphasizing the alignment of SHINE's technology with cancer treatment goals [1] Industry Impact - SHINE operates one of the largest Lu-177 production facilities in North America, contributing to advancements in cancer treatment [1] - The company's long-term goal is to commercialize fusion energy while impacting healthcare and sustainable energy sectors [1]

Core Insights - United Therapeutics (UTHR) reported Q4 2025 earnings per share (EPS) of $7.70, exceeding the Zacks Consensus Estimate of $6.78, with a year-over-year increase of 24% driven by higher product sales [1][7] - The company anticipates "double-digit revenue growth" in 2026 and aims for a $4 billion annualized revenue run rate in the second half of 2027 [2][3] Financial Performance - Q4 revenues were $790.2 million, missing the Zacks Consensus Estimate of $805 million, but reflecting a 7.3% year-over-year growth, primarily from Tyvaso and Orenitram [2] - For the full year 2025, total revenues reached $3.18 billion, an 11% increase from 2024, with net earnings of $27.86 per share compared to $24.64 in 2024 [11] Product Sales Breakdown - Combined sales of Tyvaso products were $464.3 million, up 12% year over year, although they fell short of the Zacks Consensus Estimate of $488 million [4] - Tyvaso DPI generated $338.6 million in revenue, a 24% increase year over year, aided by enhanced commercialization efforts [5] - Sales of nebulized Tyvaso were $125.7 million, down 12% due to lower volumes [8] - Orenitram sales rose 12% to $121.2 million, while Remodulin sales declined 5% to $128 million, and Unituxin sales decreased 8% to $62.3 million [8] Expenses - Research and development expenses were $139.5 million, up 4.3% year over year, reflecting increased clinical development costs [9] - Selling, general, and administrative expenses rose 13.1% to $190.6 million, driven by higher consulting and personnel costs [9] Pipeline Developments - Key phase III programs include Tyvaso for chronic fibrosing interstitial lung disease and oral ralinepag for PAH [12] - The TETON-2 study showed clinical benefits in idiopathic pulmonary fibrosis patients, with management believing it could expand Tyvaso's therapeutic reach [13] - The company is also conducting the TETON-1 study and plans to meet with the FDA to expedite regulatory review if results are favorable [14] - Top-line data from the ADVANCE OUTCOMES study for ralinepag is expected in the first half of 2026 [15]

MannKind (NasdaqGM:MNKD) Q4 2025 Earnings call February 26, 2026 09:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorChris Prentiss - CFOMichael Castagna - CEORoanna Ruiz - Senior Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorGood morning, and welcome to the MannKind Corporation fourth quarter and full year 2025 financial results earnings call. As a reminder, this call is being recorded on February 26, 2026, and will be available for replay on the MannKind Co ...

MannKind (NasdaqGM:MNKD) Q4 2025 Earnings call February 26, 2026 09:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorChris Prentiss - CFOMichael Castagna - CEORoanna Ruiz - Senior Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorGood morning, and welcome to the MannKind Corporation Q4 and full year 2025 financial results earnings call. As a reminder, this call is being recorded on February 26, 2026, and will be available for replay on the MannKind Corporation we ...

MannKind (NasdaqGM:MNKD) Q4 2025 Earnings call February 26, 2026 09:00 AM ET Speaker4Good morning, and welcome to the MannKind Corporation fourth quarter and full year 2025 financial results earnings call. As a reminder, this call is being recorded on February 26, 2026, and will be available for replay on the MannKind Corporation website shortly after this call and for approximately 90 days. This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertain ...

Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer commented on. Answering a caller’s question about the stock during the lightning round, Cramer said: Oh no, you don’t want to be in Novo Nordisk. You want to be in Eli Lilly. Novo Nordisk is really good at cutting prices. Eli Lilly’s great at making drugs. Photo by Adam Nowakowski on Unsplash Novo Nordisk A/S (NYSE:NVO) manufactures pharmaceuticals for chronic conditions, including diabetes, obesity, and rare blood or endocrine disorders. The ...

AtaiBeckley Inc. (NASDAQ:ATAI) on Thursday shared topline results from an exploratory Phase 2a trial of EMP-01, an oral R-MDMA treatment for Social Anxiety Disorder.The encouraging data highlights a favorable safety profile and significant patient improvement, which may be contributing to the stock’s upward movement from an exploratory Phase.Social Anxiety DataIn the trial, 49% of patients receiving EMP-01 were rated as “very much improved” or “much improved,” compared to only 15% in the placebo group, indi ...

Ligand Pharmaceuticals (NasdaqGM:LGND) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAnnabel Samimy - Managing DirectorJoe Pantginis - Managing DirectorJoohwan Kim - Assistant VP of BiotechnologyLauren Hay - VP of Strategic Planning and Investment AnalyticsMelanie Herman - Executive Director of Investor RelationsTavo Espinoza - CFOTodd Davis - CEOConference Call ParticipantsJohn Vandermosten - Senior AnalystMatt Hewitt - Senior Research AnalystPete Lucas - AnalystTrevor Allred - Ex ...

Ligand Pharmaceuticals (NasdaqGM:LGND) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAnnabel Samimy - Managing DirectorJoe Pantginis - Managing DirectorJoohwan Kim - Assistant VP of BiotechnologyLauren Hay - VP of Strategic Planning and Investment AnalyticsMelanie Herman - Executive Director of Investor RelationsTavo Espinoza - CFOTodd Davis - CEOConference Call ParticipantsJohn Vandermosten - Senior AnalystMatt Hewitt - Senior Research AnalystPete Lucas - AnalystTrevor Allred - Ex ...